Choosing the Right Inhaler Device for Children Can Reduce Hospitalizations

Even small improvements in healthcare delivery can have a significant impact, especially under current budget constraints. A recent study highlights the importance of selecting the appropriate valved holding chamber (VHC) when administering inhaled medication to young children experiencing acute respiratory distress. The findings, published in JAMA Pediatrics, suggest that the choice of device can substantially affect hospital admission rates and improve patient outcomes.

Acute Wheezing and Emergency Visits

Acute wheezing is a common reason for emergency department visits among preschool-aged children. The Finnish multi-center CHAMBER trial investigated the impact of VHC choice on treatment effectiveness when administering inhaled salbutamol, a bronchodilator medication.

Higher-Delivery VHCs Lead to Better Outcomes

The study revealed a significant difference in hospital admission rates based on the VHC used. Children treated with a higher-delivery VHC had a 20% hospital admission rate, compared to a 50% rate for those receiving treatment via a lower-delivery device. Children using the higher-delivery chamber exhibited lower respiratory rates and improved oxygen saturation levels post-treatment, indicating better physiological recovery. JAMA Pediatrics

Understanding Valved Holding Chambers

A valved holding chamber is a tubular device connected to a pressurized metered-dose inhaler. It helps deliver aerosolized medications effectively. For children aged 0-3 years, a face mask is used with the VHC, while older children typically inhale the medication directly from the chamber. VHCs differ in several key characteristics – shape, volume, valve design, electrostatic properties, and mask fit – all of which influence how much medication reaches the lungs. Tampere University

Challenging Common Assumptions

“Parents and clinicians often assume that VHCs are interchangeable, but our results show they are not. In small children with respiratory distress, the choice of device can make a major difference,” says Adjunct Professor Péter Csonka, principal investigator of the study, from Tampere University. Tampere University

Clinical Relevance and Future Implications

Professor Terhi Ruuska-Loewald from Oulu University Hospital adds, “Our findings are directly relevant to pediatric emergency care. By choosing a device that has been proven to deliver more medicine to the lungs of young children, we can reduce hospital admissions and improve the well-being of both children and their families.”

Previous laboratory studies indicated variations in medication delivery between VHCs, but the CHAMBER trial confirms that these differences translate into clinically meaningful benefits. These performance differences extend to other inhaled medications, emphasizing the importance of careful device selection and proper user guidance.

Study Details

The CHAMBER trial addressed the limitations of previous laboratory studies, which often used steady flow profiles or simulated adult breathing patterns. The trial accounted for the rapid, shallow breathing and low lung capacity typical of young children in respiratory distress, as well as potential issues with mask fit and patient cooperation. Tampere University

The study was published in JAMA Pediatrics on February 23, 2026. JAMA Pediatrics